Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses that infect the nose, throat, and lungs. It can cause mild to severe illness and at times can lead to death.
The best way to prevent the flu is by getting a seasonal flu vaccine each year. However, Influenza Diagnostic Tests also play an important role in detecting and managing the flu.
Types of Rapid Influenza Diagnostic Tests Tests
There are various rapid influenza diagnostic tests available globally which can diagnose influenza within 30 minutes. The major types include:
Immunochromatographic Tests
Immunochromatographic tests, also known as lateral flow immunoassays, are simple bedside tests that can provide qualitative results within 10-15 minutes. They work on the basic principle of immunochromatography and require minimal training to perform. These tests are ideal for point-of-care settings like physician offices, urgent care clinics, and emergency rooms.
Molcular Assays
Molecular assays like reverse transcriptase polymerase chain reaction (RT-PCR) tests provide sensitive and specific detection of influenza viruses within 1-2 hours. These tests amplify specific sequences in viral RNA or DNA to definitively diagnose or rule out influenza. While more complex than immunochromatographic tests, molecular assays are considered the gold standard for influenza diagnostics due to their high accuracy.
Advantages over Conventional Testing Methods
Rapid influenza diagnostic tests have several advantages over conventional viral culture and direct fluorescent antibody methods which can take days to provide results:
- Fast Turnaround Time: As mentioned earlier, rapid tests can provide results within 30 minutes, allowing for quicker clinical decision making compared to conventional tests needing 1-4 days for reporting.
- Point-of-Care Testing: The simplicity and portability of rapid tests enable near-patient or at-the-bedside testing versus sending samples to a laboratory. This is important for infection control and patient management decisions.
- Improved Patient Outcomes: Studies show rapid influenza tests lead to reductions in unnecessary antibiotic use, earlier administration of antivirals, lower healthcare costs, and decreased length of hospital stay compared to conventional methods.
- Detection of Multiple Strains: Some multiplex molecular assays have the ability to simultaneously detect influenza A and B strains as well as differentiate between subtypes like H1N1 and H3N2 in a single test. This provides expanded diagnostic information over traditional tests.
Strategic Use of Tests Improves Patient Care
Rapid influenza diagnostic tests play a pivotal role when judiciously incorporated into clinical algorithms and treatment pathways:
- Screening and Triage of Patients: Testing suspected flu cases rapidly detects true positives and guides appropriate isolation and infection control measures. It rules out unnecessary precautions for negatives.
- Targeted Antiviral Treatment: Timely administration of antivirals within 48 hours of symptom-onset improves outcomes for at-risk groups like young children, elderly, and pregnant women. Rapid tests help meet the narrow treatment window.
- Reduced Testing for Non-Flu Cases: By swiftly ruling out influenza, rapid tests avoid unnecessary full respiratory panels and antibiotics for negative patients mitigating over-testing and healthcare costs.
- Surveillance and Outbreak Management: Aggregate testing data assists public health officials in timely surveillance, detection of mutants or shifts in circulating strains, and control of institutional or community outbreaks.
Growing Adoption across Global Healthcare Systems
Rapid influenza diagnostic tests are witnessing steadily rising adoption across healthcare systems worldwide owing to their benefits over conventional methods:
- US Market: The US rapid flu test market was valued at $344 million in 2020 and is estimated to reach $520 million by 2026, according to Allied Market Research. The growing elderly population, test accuracy gains, and emphasis on outpatient treatment are fueling demand.
- Europe: Major European countries like the UK, Germany, France, and Italy have inclusion of rapid flu tests in their national testing guidelines. The regional market was worth $193 million in 2020 and is projected to hit $282 million by 2026 at a 6.2% CAGR, as stated in a Grand View Research report.
- Asia-Pacific: With rising healthcare expenditures, increasing awareness, and government programs promoting rapid testing usage, the Asia-Pacific market exhibited the fastest 14.1% CAGR between 2021-2026, per credible sources. China, Japan, and India have emerged as lucrativeAPAC markets.
- Other Regions: Regions including Latin America, the Middle East, and Africa are also witnessing expansionalbeit at a slower pace currently given infrastructure and budget limitations in certain nations. However, the growing disease burden indicates future rapid test uptake.
This global adoption trend underlines the clinical and economic case for rapid influenza diagnostic testing within national healthcare responses as an important supplementary tool for improving patient outcomes and mitigating flu's societal effects. Public health authorities will continue advocating their judicious incorporation.
Get more insights on this topic: https://benstiller.hashnode.dev/rapid-influenza-diagnostic-tests-rapid-influenza-diagnostic-tests-see-strong-growth-amidst-pandemic/
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)